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http://dx.doi.org/10.1016/j.stemcr.2016.04.013SUMMARYDe novo ASXL1 mutations are found in patients with Bohring-Opitz syndrome, a disease with severe developmental defects and early
childhood mortality. The underlying pathologic mechanisms remain largely unknown. Using Asxl1-targeted murine models, we found
that Asxl1 global loss as well as conditional deletion in osteoblasts and their progenitors led to significant bone loss and a markedly
decreased number of bone marrow stromal cells (BMSCs) compared with wild-type littermates. Asxl1/ BMSCs displayed impaired
self-renewal and skewed differentiation, away from osteoblasts and favoring adipocytes. RNA-sequencing analysis revealed altered
expression of genes involved in cell proliferation, skeletal development, andmorphogenesis. Furthermore, gene set enrichment analysis
showed decreased expression of stem cell self-renewal gene signature, suggesting a role of Asxl1 in regulating the stemness of BMSCs.
Importantly, re-introduction of Asxl1 normalized NANOG and OCT4 expression and restored the self-renewal capacity of Asxl1/
BMSCs. Our study unveils a pivotal role of ASXL1 in the maintenance of BMSC functions and skeletal development.INTRODUCTION
Bone marrow stromal cells (BMSCs) are multi-potent
progenitor cells with self-renewal capabilities and multi-
lineage differentiation potentials, including osteogenesis
and adipogenesis (Bianco et al., 2008; Teitelbaum, 2010;
Uccelli et al., 2008; Ye et al., 2012). The relation between
osteogenesis and adipogenesis in BMSCs is critical for
normal bone homeostasis. Skewed cell fate of BMSCs
can lead to developmental defects. For example, inhibi-
tion of adipogenesis may enhance bone growth and repair
(Kawai and Rosen, 2010; McCauley, 2010). More recently,
Mendez-Ferrer and others reported that the final cell-fate
decision of BMSCs relies on an orchestrated activation
of lineage-specific genes and repression of genes gov-
erning cell stemness or commitment to other lineages
(Mendez-Ferrer et al., 2010; Takada et al., 2009; Wei
et al., 2011).
Bohring-Opitz syndrome (BOS) is a heterogeneous ge-
netic condition characterized by severe developmental
delay, characteristic craniofacial appearance, fixed con-
tractures of the upper limbs, abnormal posture, feeding914 Stem Cell Reports j Vol. 6 j 914–925 j June 14, 2016 j ª 2016 The Autho
This is an open access article under the CC BY-NC-ND license (http://creativdifficulties, severe intellectual disability, fetal microsomia,
and failure to thrive (Bohring et al., 2006; Hastings et al.,
2011; Oberklaid and Danks, 1975). Most patients die
in early childhood due to developmental deficits, unex-
plained bradycardia, obstructive apnea, or pulmonary in-
fections (Hastings et al., 2011). In 2011, Hoischen et al.
(2011) identified de novo nonsense mutations of the addi-
tional sex combs-like 1 gene (ASXL1) in patients with BOS.
Somatic ASXL1 alterations have also been reported in
elderly patients with myeloid malignancies, including
myelodysplastic syndrome, chronic myelomonocytic leu-
kemia, and acute myeloid leukemia (Carbuccia et al.,
2009; Gelsi-Boyer et al., 2009).
ASXL1 belongs to the enhancer of trithorax group
(TrxG) and polycomb group (PcG) (ETP), and geneti-
cally interacts with CBX2 in mice (Fisher et al., 2010).
PcG and trxG proteins are key regulators for the expres-
sion of numerous developmental genes by silencing or
activating gene expression, respectively. The ETP genes
encode proteins required for both maintenance of activa-
tion and silencing, as shown by simultaneous anterior
and posterior transformations caused by failure to activater(s)
ecommons.org/licenses/by-nc-nd/4.0/).
or repress Hox genes. In an Asxl1 mutant mouse model,
Fisher et al. (2010) reported an alteration of the axial
skeleton in newborn pups involving anterior and poste-
rior transformations. However, the cellular and molecu-
lar mechanisms by which ASXL1 mutation causes BOS
remain unclear.
We have recently reported that Asxl1 null mice are
smaller in size and exhibit anophthalmia (Wang et al.,
2014). In this study, we aimed to unveil the cellular and
molecular mechanisms underlying the pathogenesis of
ASXL1 loss-mediated skeletal defects. Our study demon-
strated that nullizygous loss of Asxl1 led to multiple skel-
etal developmental defects, including runting, markedly
reduced bone mineral density (BMD), microcephaly, and
hypoplastic supraorbital ridges, closely reminiscent of
BOS.We further identified that the defective skeletal devel-
opment was associated with an impaired self-renewal and
skewed lineage commitment of BMSCs, away from osteo-
blast and favoring adipocyte differentiation. Moreover,
RNA-sequencing (RNA-seq) analysis demonstrated that
Asxl1 loss altered the expression of genes that are critical
for stem cell self-renewal. Importantly, re-introduction of
Asxl1 into Asxl1/ BMSCs restored BMSC self-renewal
and lineage commitment. These data indicate a pivotal
role of ASXL1 in the maintenance of BMSC functions and
skeletal development.RESULTS
Loss of Asxl1 Impairs BMSC Self-Renewal and
Differentiation Capacity
Self-renewal and multi-lineage differentiation are the two
key characteristics of BMSCs. We first assessed whether
Asxl1 loss alters BMSC cellular functions. qPCR was per-
formed to ensure thatAsxl1was successfully deleted.While
Asxl1 mRNA was detected in wild-type (WT) BMSCs, no
Asxl1 mRNA was detected in Asxl1/ BMSCs, indicating
successful deletion of Asxl1 (Figure S1A). Asxl1 null mice
were generated by replacing part of the Asxl1 exon 1
sequence with nlacZ/nGFP (inserted 6 bp upstream of the
start codon) as previously reported (Wang et al., 2014).
The targeted allele results in transcription of nGFP mRNA
instead of Asxl1 (the endogenous ATG was disrupted). We
examined GFP expression in the BMSCs from Asxl1+/
mice by flow-cytometric analysis to determine whether
Asxl1 is expressed in BMSCs. The CD45CD105+CD44+
CD73+CD146+CD90+ cell population, defined as BMSCs
(Barry and Murphy, 2013; Joyce and Pollard, 2009), were
GFP positive (Figure S1B), suggesting expression of ASXL1
in BMSCs.
Having confirmed ASXL1 expression in WT BMSCs, we
next examined the effect ofAsxl1 deletion onBMSC expan-sion. [3H]Thymidine incorporation assays revealed that
Asxl1 ablation diminished BMSC proliferation (Figure 1A).
Mendez-Ferrer et al. (2010) reported that Nestin+ BMSCs
form non-adherent mesenspheres that can be serially re-
plated in culture due to their self-renewal capability. We
next performed clonal mesensphere cultures to determine
whether loss of Asxl1 altered BMSC self-renewal capacity.
The clonal mesensphere formation potential of Asxl1/
BMSCs was significantly reduced compared with WT
BMSCs when equal numbers of BMSCs were plated (Fig-
ure 1B). WT mesenspheres were 414 ± 28.5 mm in
diameter and the secondary spheres were 133 ± 20 mm in
diameter (Figures 1C and 1D). In contrast, Asxl1/mesen-
spheres were significantly smaller (187.5 ± 24 mm in diam-
eter) and exhibited a decreased capacity to form secondary
spheres (64 ± 4 mm in diameter) (Figures 1C and 1D). Flow
cytometric analysis revealed that the cells of the
mesensphere colonies were Nestin+, CD51+, CD105+, and
CD146+ (Figure S1C), confirming that these cells were
indeed BMSCs.
BMSCs have multi-lineage differentiation potential,
including the ability to form osteoblasts and adipocytes
(Pittenger et al., 1999). To evaluate the effect of Asxl1 dele-
tion on BMSCdifferentiation, we performed osteoblast and
adipocyte differentiation assays. Liquid culture of BMSCs
with different culture conditions verified that Asxl1 dele-
tion diminished osteoblast differentiation, as evidenced
by minimal alkaline phosphatase-positive (ALP+) expres-
sion and increased oil red O-positive (+) cells in Asxl1/
cultures compared with WT cultures (Figures 1E and 1F,
respectively). Chondrocyte differentiation assays showed
that Asxl1 deletion did not affect chondrocyte differentia-
tion from BMSCs (data not shown). Collectively, these
data indicate that loss of Asxl1 impairs BMSC self-renewal
and skews BMSC lineage commitment away from osteo-
blasts but in favor of adipocytes.
Asxl1 Deletion Reduces BMSC Frequency and Alters
BMSC Fates in Mice
To examine whether Asxl1 deletion alters the BMSC
frequency in vivo, we next performed flow cytometric
analysis on bone marrow cells stained with a cocktail
of antibodies, including CD45, CD44, CD105, CD73,
CD146, and CD90 (Barry and Murphy, 2013; Joyce and
Pollard, 2009). A significant reduction in the CD45
CD44+CD105+CD73+CD146+CD90+ BMSC population was
observed in the bone marrow of Asxl1/ mice compared
withWT littermates (Figure 2A). Consistently, colony-form-
ing-unit fibroblast (CFU-F) assay, a well-established method
to determine BMSC frequency in vivo, revealed a signifi-
cantly reduced frequency ofCFU-F inAsxl1/ bonemarrow
compared with WT controls (Figures 2B and 2C). To deter-
minewhether the decreasedCFU-F frequencywas due solelyStem Cell Reports j Vol. 6 j 914–925 j June 14, 2016 915
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Figure 1. Asxl1 Is Required for BMSC Self-Renewal
and Differentiation
(A) Proliferation assays show impaired growth of
Asxl1/ BMSCs compared with WT (n = 4 mice per
genotype from at least three independent experi-
ments).
(B) The frequency of non-adherent mesenspheres
from Asxl1/ BMSCs is significantly decreased
compared with WT BMSCs. An equal number of BMSCs
were plated (n = 5 mice per genotype from three
independent experiments).
(C) Self-renewal capacity of BMSCs was assayed by
clonal non-adherent sphere formation. Asxl1/
BMSCs (n = 10 mice) exhibit a significantly decreased
sphere diameter compared with WT BMSCs (n = 8
mice). Scale bar represents 100 mm.
(D) The formation of secondary spheres fromAsxl1/
BMSCs is also significantly reduced compared with WT
BMSCs (n = 5 mice per genotype).
(E) ALP staining shows significantly decreased
osteoblast differentiation by Asxl1/ BMSCs (n = 11
mice) as compared with WT BMSCs (n = 9 mice).
(F) Oil red O staining shows significantly increased
adipocyte differentiation by Asxl1/ BMSCs
compared with WT BMSCs (n = 11 mice per genotype).
Scale bar represents 50 mm.
Data are presented as mean ± SEM. **p < 0.005,
***p < 0.001. See also Figure S1.to the decreased frequency of BMSCs in Asxl1/ bone
marrow, we performed CFU-F assays with an equal number
of BMSCs. Significantly fewer CFU-F were formed by
Asxl1/ BMSCs compared with WT BMSCs (Figure S1D).
These data indicate that Asxl1 deletion decreases the BMSC
pool and their CFU-F forming ability in the bone marrow
in vivo.
To further evaluate the effect of Asxl1 loss on BMSC
differentiation in vivo, we subsequently performed CFU-
osteoblast and CFU-adipocyte differentiation assays using
primary bone marrow mononuclear cells (BMMNCs)
from WT and Asxl1/ mice. Compared with WT controls,
Asxl1/BMMNCs gave rise to a significantly reducednum-
ber of ALP+ osteoblastic colonies (Figure 2D). In contrast,
the total number of oil red O+ colonies and the ratio of oil
red O+ colonies to CFU-F were dramatically increased in
Asxl1/ cultures (Figure 2E). Collectively, these data indi-
cate that loss ofAsxl1 impairs BMSC self-renewal and skews
BMSC lineage commitment in vivo (Figure 2F).
Genetic Deletion of Asxl1 Leads to Multiple Skeletal
Deficits Reminiscent of Human Bohring-Opitz
Syndrome
Asxl1-knockout mice are smaller in size, and some mice
have anophthalmia (Wang et al., 2014). Using alizarin
red S/Alcian blue 8GX staining, we showed that loss of916 Stem Cell Reports j Vol. 6 j 914–925 j June 14, 2016Asxl1 resulted in 30% reduction in body size compared
with littermate controls (Figure S2A). A kinetic quantitative
measurement of body size and body weight revealed sig-
nificant delays in growth of Asxl1/ mice over time
compared with WT littermates (Figures S2B and S2C).
Asxl1/ mice also exhibited a significant reduction in
skull size compared with their littermate controls, reminis-
cent of the microcephaly in BOS patients (Figure S2D).
Peripheral dual-energy X-ray absorptiometry (pDEXA) re-
vealed significantly reduced BMD in the distal femurs
of Asxl1/ mice compared with their littermate controls
(Figure S2E). Microcomputed tomography (mCT) demon-
strated a marked reduction of bone volume fraction in
Asxl1/mice compared with their littermate controls (Fig-
ure S2F). Furthermore, hypoplastic supraorbital ridges, a
characteristic of BOS, were observed in Asxl1/ mice
(Figure S2G).
Labeling bones with fluorochrome markers provides a
method to study the dynamic changes of bone formation
(Warden et al., 2005; Wu et al., 2011). We next examined
bone remodeling in WT and Asxl1/ mice with a fluores-
cent labeling assay. An45% reduction in the bone forma-
tion rate per bone surface (BFR/BS)was observed inAsxl1/
mice comparedwithWTcontrolmice (Figures S2HandS2I).
These data demonstrate that loss of Asxl1 in mice impairs
skeletal development.
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Figure 2. Loss of Asxl1 Impairs BMSC Self-
Renewal and Differentiation in Mice
(A) Quantitation of percentage of CD45
CD105+CD44+CD73+CD146+CD90+ cell pop-
ulations (BMSCs) in the bone marrow of
WT (n = 9 mice) and Asxl1/ (n = 10 mice,
3 weeks old) by flow cytometry.
(B and C) The frequencies of CFU-F per femur
(B) and per 13 106 BMMNCs (C) from WT and
Asxl1/ mice are shown (n = 6 mice per
genotype).
(D) The frequencies of CFU-osteoblast (ALP+)
per femur are shown (top panel). Represen-
tative ALP staining of WT and Asxl1/
osteoblastic colonies cultured in osteogenic
culture medium from BMMNCs. WT (n = 8
mice) and Asxl1/ (n = 7 mice).
(E) The ratio of oil red O+ adipocytes to total
colonies demonstrates enhanced adipocyte
differentiation in Asxl1/ BMSCs compared
with WT BMSCs (n = 3 mice per genotype).
Scale bar represents 200 mm.
(F) Pie chart illustrates that loss of Asxl1
impairs BMSC self-renewal and skews BMSC
lineage commitment away from osteoblasts,
favoring adipocytes. Data represent the
means of four independent experiments.
Data are presented as mean ± SEM. ***p <
0.001. See also Figure S1.Conditional Deletion of Asxl1 in Osteoblasts
Recapitulates the Developmental Defects Observed in
Asxl1/ Mice
To further delineate the cell-autonomous role of ASXL1 in
mediating BMSC cellular functions, we crossed Asxl1
floxed allele mice (Asxl1fl/fl) (Abdel-Wahab et al., 2013)
with transgenicmice harboringOsterix-Cre (Osx-Cre, specif-
ically expressed in the pre-osteoblastic and osteoblastic lin-
eages) to generate OsxCre;Asxl1fl/fl mice (OsxCre;Asxl1D/D)
(Figure S3A). Similar to Asxl1/ mice, X-ray images of
OsxCre;Asxl1D/D mice at 3 weeks of age demonstrated
dwarfism compared with Asxl1fl/fl control mice (Figure 3A).
Serial measurement of body weight revealed a consistently
lower body weight at varying ages of OsxCre;Asxl1D/D mice
compared with age-matched littermate control mice (Fig-
ure 3B). pDEXA scans demonstrated reduced whole-body
BMD and distal femoral BMD in OsxCre;Asxl1D/D mice
compared with their littermate controls (Figures S3B andStem Ce3C). mCT further revealed diminished
trabecular bone volume and trabecular
number along with increased trabec-
ular spacing in OsxCre;Asxl1D/D mice
compared with WT controls (Figures
3D, 3E, and S3C). In addition, thecortical bone thickness of the mid-shaft femur was signifi-
cantly reduced compared with control mice (Figure S3D).
A greater than 50% reduction in the mineral apposition
rate and a 43% reduction in the BFR/BS were observed in
OsxCre;Asxl1D/Dmice compared with control mice (Figures
3F and 3G). These data reinforce the cell-autonomous role
of Asxl1 deletion in defective skeletal development.
To determine whether the BMSC frequency is affected
in OsxCre;Asxl1D/D mice, we examined the percentage of
PDGFRa+CD45TER119CD31 BMSCs by flow cytometry
(Worthley et al., 2015; Zhou et al., 2014). A significant
reduction in BMSCs was observed in the bone marrow of
OsxCre;Asxl1D/D mice compared with littermate controls
(Figures 3H and S3E). PDGFRa+CD45TER119CD31
BMSCs from OsxCre;Asxl1D/D and controls contained a
similar proportion of Sca1+ and CD51+ cell populations
(Figure S3E). Consistently, a significant reduction in
frequency of CFU-F was observed in the bone marrow ofll Reports j Vol. 6 j 914–925 j June 14, 2016 917
OsxCre;Asxl1D/D mice compared with littermate control
mice (Figure 3I). When plating an equal number of cells
from CFU-F, we found a significant reduction of plating ef-
ficiency in OsxCre;Asxl1D/D BMSCs compared with control
BMSCs (Figure S3F), suggesting an impaired self-renewal
capacity in OsxCre;Asxl1D/D mice. CFU-osteoblast differen-
tiation assays further confirmed that BMMNCs from
OsxCre;Asxl1D/D mice gave rise to a significantly reduced
number of ALP+ osteoblastic colonies than those of control
mice (Figure 3J). The ratio of ALP+ osteoblast colonies to to-
tal colonies was significantly decreased in OsxCre;Asxl1D/D
mice compared with control mice, further confirming
the impaired osteoblast differentiation in OsxCre;Asxl1D/D
mice (Figure 3K). Collectively, these data further validate
our finding that loss of Asxl1 decreases the BMSC pool
and impairs osteoblast differentiation.
Asxl1 Loss Dysregulates Transcriptional Programs to
Induce BMSC Lineage Commitment
To determine whether loss of Asxl1 alters gene expression
profiles in BMSCs, we next performed RNA-seq on WT and
Asxl1/ BMSCs. Compared with WT BMSCs, Asxl1/
BMSCs exhibited a distinct gene expression signature with
a total of 338 dysregulated genes. Among those, 182 genes
were upregulated and 156 genes downregulated (Figure 4A).
Gene ontology (GO) analysis and enrichment mapping
(Merico et al., 2010; Pinto et al., 2010) demonstrated that
the downregulated genes in Asxl1/ BMSCs were enriched
in skeletal development and morphogenesis (Figure 4B).
Furthermore, gene set enrichment analysis (GSEA) (Subra-
manian et al., 2005) indicated that loss ofAsxl1 significantly
decreased expression of stem cell signature genes in BMSCs
(Figure 4C). By contrast, upregulated geneswere enriched in
cell development/differentiation and tissuemorphogenesis
(Figure S4).
To further validate the altered expression of key genes
required for BMSC self-renewal and differentiation, we per-
formed qPCR and western blotting with WT and Asxl1/
BMSCs. qPCR revealed that the mRNA expression of genes
critical for stem cell pluripotency, includingNanog, Pou5f1,
and Sox2, was significantly reduced in Asxl1 null BMSCs
compared with WT BMSCs (Figure 4D), correlating with
the impaired self-renewal of Asxl1 null BMSCs. Consis-
tently, western blot analysis revealed markedly reduced
NANOG, OCT4, and SOX2 protein levels in Asxl1 null
BMSCs compared with WT cells (Figure 4E). Furthermore,
mRNA expression of Runx2, Sp7, Bglap, and Alpl, genes
critical for osteogenic differentiation, was also reduced in
Asxl1 null BMSCs compared with WT BMSCs (Figure 4F).
By contrast, mRNA expression of Pparg, Cebpa, Fabp4,
and Lpl, genes controlling adipogenic differentiation, was
dramatically increased in Asxl1-deficient BMSCs compared
withWT BMSCs (Figure 4G). Altogether, these data suggest918 Stem Cell Reports j Vol. 6 j 914–925 j June 14, 2016that ASXL1 regulates BMSC fates through controlling
the expression of genes critical for BMSC self-renewal and
lineage commitment.Re-expression of Asxl1 Rescues Self-Renewal and
Osteoblast/Adipocyte Differentiation in Asxl1/
BMSCs
To determine whether impaired self-renewal of Asxl1/
BMSCswas a direct consequence of theAsxl1 loss, we trans-
duced WT Asxl1 (with a FLAG tag for easy detection) into
Asxl1/ BMSCs using a lentiviral system. Asxl1/ BMSCs
transduced with empty vector were used as a control. The
expression of ASXL1 was confirmed by western blot anal-
ysis (Figure 5A) and qPCR (Figure S5). Re-expression of
WTAsxl1 inAsxl1/BMSCs significantly increasedmesen-
sphere size (Figure 5B) and restored levels of NANOG and
OCT4 (Figure 5C), suggesting a restoration of self-renewal
capacity of Asxl1 null BMSCs.
To determine whether re-expression of Asxl1 could
rescue the aberrant lineage commitment of Asxl1/
BMSCs, we repeated the osteoblast and adipocyte differen-
tiation assays. Re-expression of Asxl1 in Asxl1/ BMSCs
increased osteoblast differentiation (Figure 5D) while in-
hibiting adipocyte differentiation (Figure 5E) compared
with empty vector controls. qPCR confirmed that the
expression levels of genes controlling osteoblast and adipo-
cyte differentiation, including Runx2, Sp7, Pparg, and
Cebpa, were restored (Figures 5F and 5G).DISCUSSION
Denovononsensemutations ofASXL1 account for approx-
imately 75% of BOS cases (Hoischen et al., 2011; Magini
et al., 2012; Russell et al., 2015). This disease is fatal, and
the underlying cellular and molecular mechanisms remain
unknown. Here, we report that global loss of Asxl1 or con-
ditional deletion in osteoblasts and their progenitors leads
to multiple developmental defects, including dwarfism,
hypoplastic supraorbital ridges, microcephaly, low bone
mass, and growth retardation. In addition, Asxl1 loss
impairs self-renewal capacity and skews differentiation
away fromosteoblasts while in favor of adipocytes. Further-
more, deletion of Asxl1 dysregulates the expression of
genes controlling BMSC fates. Our study, therefore,
demonstrates a pivotal role of ASXL1 in bone homeostasis.
The balance between BMSC self-renewal and differentia-
tion is critical for skeletal homeostasis (Ito and Suda, 2014;
Sambasivan and Tajbakhsh, 2007). In this study, we found
that Asxl1 null mice exhibited markedly reduced fre-
quencies of BMSCs and CFU-F. Asxl1 loss in BMSCs
reduced mesensphere formation and diminished re-plating
capability, indicating impaired BMSC self-renewal. The
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Figure 3. Loss of Asxl1 in Pre-osteoblasts and Their Progenies Leads to BOS-like Phenotypes in Mice
(A) High-resolution X-ray images demonstrate runting of OsxCre;Asxl1D/D mice compared with Asxl1fl/fl littermates at 3 weeks of life.
(B) Serial body weight measurement of OsxCre;Asxl1D/Dmice and Asxl1fl/fl littermates (n = 6 mice per genotype). Mice were weighed weekly
on the same date and time.
(C) Distal femur BMD of 3-week-old Asxl1fl/fl (n = 4 mice) and OsxCre;Asxl1D/D (n = 6 mice).
(D and E) mCT analysis shows a significantly reduced bone volume (D) and trabecular bone (E) in OsxCre;Asxl1D/D (n = 6 mice) compared
with Asxl1fl/fl controls (n = 4 mice). Scale bar represents 200 mm.
(F and G) Dynamic bone histomorphometry was performed using alizarin labeling. The mineral apposition rate (MAR, F) and bone formation
rate (BFR/BS, G) are significantly decreased in OsxCre;Asxl1D/D (n = 6 mice) versus controls (n = 4 mice). Scale bar represents 20 mm.
(H) Quantitation of percentage of PDGFRa+CD45TER119CD31 BMSCs in the bone marrow of OsxCre;Asxl1D/D (n = 5 mice) and littermate
controls (n = 4 mice, 5 weeks old).
(I) The frequencies of CFU-F per femur from Asxl1fl/fl (n = 5 mice) and OsxCre;Asxl1D/D (n = 7 mice) are shown.
(legend continued on next page)
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frequencyofCFU-F inAsxl1/bonemarrowwas even lower
than the percentage of BMSCs as determined by flow-cyto-
metric analysis. Thus, the dramatic reduction of CFU-F
capacity ofAsxl1/ bonemarrow is likely a combined effect
of both reduced frequency and impaired self-renewal
of BMSCs. In vitro differentiation assays also revealed
markedly reduced osteoblast differentiation potential in
Asxl1/ BMSCs. In contrast, Asxl1/ BMSCs exhibited an
increased propensity for adipocyte differentiation, which
is consistent with previous findings demonstrating that
ASXL1 negatively regulates adipogenesis in a 3T3-L1 cell
line (Park et al., 2011). These results implicate ASXL1 as a
critical regulator of BMSC self-renewal and lineage commit-
ment, providing a cellular mechanism underlying defective
skeletal homeostasis associated with the Asxl1 deletion.
ASXL1 mutations occur de novo in BOS patients, and it is
therefore expected that multiple cell lineages are affected.
To date, however, the specific cell lineages harboring
ASXL1 mutations in BOS patients remain unknown, and
further clinical studies are warranted.
Thephenotype and fate of a givencell relies on theprecise
control of gene expression by complex transcriptional and
epigenetic networks. Such regulation of gene expression is
essential for proper differentiation, cellular function, devel-
opment, and homeostasis (Feng et al., 2010; Reik, 2007).
Histone modifications are complex, post-translational
regulatory events that play pivotal roles in governing global
gene expressionprograms.Althoughextensive studieshave
focused on the identification of intrinsic targets of tran-
scription factors regulating cellular fate and functions of
BMSCs, the epigenetic events that control BMSC identity
and/or functions remain largely unknown. In vitro studies
indicate that histone modifications (including methyl-
ation and acetylation) are a key epigenetic means for gene
regulation that contribute to osteogenic lineage determina-
tion (Rui et al., 2015; Tan et al., 2009).
ASXL1 regulates epigenetic marks and transcription
through interaction with polycomb complex proteins
and various transcription activators and repressors (Boult-
wood et al., 2010; Cho et al., 2006; Scheuermann et al.,
2010). We and others have previously reported that loss
of Asxl1 reduces global H3K27me3 and H3K4me3 levels
in myeloid progenitor cells (Abdel-Wahab et al., 2012,
2013; Wang et al., 2014). Further studies aiming to identify
the chromatin and histone markers governing gene tran-
scription for self-renewal and lineage-specific activation
or repression in Asxl1 deleted BMSCs are ongoing.(J) The frequencies of CFU osteoblasts per femur are shown (top pane
osteogenic culture medium from OsxCre;Asxl1D/D (n = 5 mice) and As
(K) Ratio of ALP+ osteoblasts to total colonies demonstrates impaired
with littermate controls (n = 3 mice).
Data are presented as mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0
920 Stem Cell Reports j Vol. 6 j 914–925 j June 14, 2016Manipulation of epigenetic mechanisms holds great
promise for the future treatment of metabolic bone dis-
eases, cancer, and a multitude of other human disease
states. A better understanding of the epigenetic regulation
in these processes is required for the development of po-
tential pharmacological agents with sufficient specificity
to precisely modulate chromatin remodeling on a global
scale. TheAsxl1-deficientmurinemodel provides a compel-
ling system to achieve such insights in the context of the
human disease BOS, for which the underling molecular
basis was previously unknown.EXPERIMENTAL PROCEDURES
ASXL1Murine Models
The generation ofAsxl1:nlacZ/nGFP knockin andAsxl1fl/flmice has
been previously described (Abdel-Wahab et al., 2013; Wang et al.,
2014). Osx-Cre transgenic mice were purchased from Jackson Lab-
oratories. All mice were bred on a C57BL/6 genetic background. All
protocols were approved by the Institutional Animal Care and Use
Committee at University of Miami Miller School of Medicine.BMSC Culture and Lineage Differentiation Assays
BMSCs were generated from each experimental group of mice as
previously described (Wu et al., 2006). In brief, BMSCs were sepa-
rated by low-density gradient centrifugation from 3- to 4-week-
old mice and then resuspended and cultured in mouse MesenCult
medium (MesenCult basal media plus 20% of MesenCult Supple-
mental; Stem Cell Technologies) at 37C and 5% CO2. When the
cultures reached 80%–90% confluence, cells were trypsinized
and re-plated. BMSCs of identical passage number (between pas-
sages 3 and 5) were used for experiments.
For osteoblast differentiation, 5 3 104 BMSCs were cultured
for 7 days in 6-well plates using osteogenic differentiationmedium
(MesenCult medium supplemented with 107 M dexamethasone,
50 mg/ml ascorbic acid, and 10 mM b-glycerophosphate). For
induction of adipocyte differentiation in vitro, 1 3 105 BMSCs
were plated in 6-well tissue-culture plates and cultured with
adipogenic differentiation medium (MesenCult medium supple-
mented with 107 M dexamethasone, 450 mM isobutylmethyl-
xanthine, 1 mg/ml insulin, and 200 mM indomethacin). For
chondrocyte differentiation assays, 1 3 105 BMSCs were plated
in 6-well plates and cultured with chondrogenic differentiation
medium (osteogenic differentiation medium supplemented with
10 ng/ml transforming growth factor b3).
Mesensphere Assays
For clonal mesensphere formation, BMSCs were plated at clonal
density (1,000 cells/cm2) in ultralow adherent 24-well platesl). Representative ALP staining of osteoblastic colonies cultured in
xl1fl/fl (n = 3 mice) BMMNCs.
osteoblast differentiation in OsxCre;Asxl1D/D (n = 5 mice) compared
.001. See also Figures S2 and S3.
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Figure 4. Asxl1 Deletion Alters the Expression of Genes Critical for BMSCs Self-Renewal and Differentiation
(A) The heatmap shows clustering of differentially expressed genes between WT and Asxl1/ BMSCs (p < 0.05, FDR < 0.25). Light purple
and light blue indicate 182 up- and 156 downregulated genes, respectively.
(B) The enrichment map helps visualize the network of KEGG pathways and GO terms enriched with downregulated genes in Asxl1/
BMSCs. Nodes and ovals indicate enriched functional gene sets (p < 0.01 and FDR < 0.25 in DAVID) and functional clusters, respectively.
Edges indicate overlap between the enriched gene sets; thickness represents significance. Only edges with a Fisher’s exact test nominal p
value smaller than 104 were visualized. Color intensity is proportional to enrichment significance.
(C) The GSEA plot shows decreased gene expression of the embryonic stem cell signature (Wong et al., 2008) in Asxl1/ BMSCs compared
with WT BMSCs. The normalized enrichment score (NES), p value, and FDR are shown.
(D) qPCR analysis shows that expression levels of the pluripotent marker genes Nanog, Pou5f1, and Sox2 are significantly lower in Asxl1/
BMSCs than in WT BMSCs (n = 6 mice per genotype).
(E) Western blot analysis shows that the protein levels of NANOG, OCT4, and SOX2 are decreased in Asxl1/ BMSCs compared with WT
BMSCs.
(legend continued on next page)
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Figure 5. Re-expression of ASXL1 Rescues
the Aberrant Cellular Phenotypes of
Asxl1/ BMSCs
(A) Western blot analysis shows the expres-
sion of FLAG-ASXL1 protein in Asxl1/
BMSCs transduced with empty vector control
or ASXL1 expression vector (FLAG-Asxl1).
(B) Mesensphere assay shows the self-
renewal capacity of WT and Asxl1/ BMSCs
expressing either empty vector or FLAG-Asxl1
as indicated. Top bars represent the mean
mesensphere diameter (mm) from three
independent experiments. Representative
mesensphere photomicrographs are labeled
accordingly. Scale bar represents 200 mm.
(C) Western blot analysis for NANOG and
OCT4 in WT and Asxl1/ BMSCs expressing
either empty vector or FLAG-Asxl1.
(D) ALP staining of osteoblast cultures of
WT BMSCs and Asxl1/ BMSCs expressing
empty vector or FLAG-Asxl1 as indicated.
Top bars represent the relative ALP+ ac-
tivity from four independent experiments.
Bottom panel shows representative photo-
micrographs of ALP staining cultures. Scale
bar represents 200 mm.
(E) Oil red O staining of adipocyte cultures
of WT or Asxl1/ BMSCs expressing either
empty vector or FLAG-Asxl1 as indicated. Top
bars represent the number of oil red O+ cells in
cultures of WT or Asxl1/ BMSC expressing
either empty vector or FLAG-Asxl1 from four
independent experiments. Bottompanel shows
representative photomicrographs of oil red O+
staining cells. Scale bar represents 50 mm.
(F) qPCR shows the expression of osteoblast
differentiation genes (Runx2, Sp7, and Alpl)
in WT and Asxl1/ BMSCs transduced with
FLAG-Asxl1 or empty vector in six indepen-
dent experiments.
(G) qPCR shows the expression of adipocyte differentiation genes in WT and Asxl1/ BMSCs with or without transduction of FLAG-Asxl1
from four independent experiments.
Data are presented as mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.001. See also Figure S5.(Corning) as previously described (Mendez-Ferrer et al., 2010;
Pinho et al., 2013). The growth medium contained 15% chicken
embryo extract (Fisher Scientific), 0.1 mM b-mercaptoethanol,
1% non-essential amino acids, 1% N2 and 2% B27 supple-
ments (Gibco), basic fibroblast growth factor, insulin-like growth
factor-1, epidermal growth factor, platelet-derived growth factor,(F) qPCR analysis shows decreased expression levels of the osteoblast m
WT BMSCs (n = 10 mice per genotype).
(G) qPCR analysis shows significantly increased expression of the ad
BMSCs compared with WT BMSCs (n = 4 mice per genotype).
Data are presented as mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0
922 Stem Cell Reports j Vol. 6 j 914–925 j June 14, 2016and oncostatin M (Peprotech) (20 ng/ml) in DMEM/F12 (1:1)/hu-
man endothelial (Gibco) (1:2). The cultures were maintained at
37C in a 5% CO2 water-jacketed incubator and left untouched
for 1 week to prevent cell aggregation in low-density cultures.
Half of the medium was changed weekly. The mesensphere col-
onies were detached with trypsin, and the cells were mechanicallyarker genes (Runx2, Bglap, Sp7, and Alpl) in Asxl1/ BMSCs versus
ipocyte marker genes (Pparg, Cepba, Fabp4, and Lpl) in Asxl1/
.001. See also Figure S4.
dispersed and re-plated back into ultralow adherent plates with
culture medium. Secondary mesenspheres were counted after
7 days in culture.
Generation of Stably Asxl1-Transduced BMSCs
The full-length mouse Asxl1 cDNA with an N-terminal FLAG
tag was cloned and then subcloned into the lentiviral vector.
The empty vector was used as a control. All constructs were vali-
dated by direct sequencing prior to lentiviral generation. BMSCs
were split approximately 16 hr prior to transduction and then
transduced overnight with concentrated supernatants. Medium
was replaced the next day, and transduced cells were cultured
and expanded. EGFP+ cells were sorted using a FACS Vantage
flow cytometer. Before further experiments, transduction and
selection efficiency were verified by qPCR and western blot
analysis.
Gene Expression Analysis by qPCR and RNA-Seq
Gene of interest mRNA levels were determined by real-time qPCR.
Total RNA was extracted with TRIzol reagent (Ambion). qPCR was
performed in triplicate using an ABI 7500 with SYBR Green PCR
kits (Applied Biosystems). mRNA levels were normalized to house-
keeping gene b-actin expression. All qPCRprimers used are listed in
Table S1.
RNA-Seq reads were aligned to the mouse genome refer-
ence sequence (GRCm38/mm10) using TopHat (Trapnell et al.,
2012) with a tolerance of two mismatches. Cuffdiff (Trapnell
et al., 2012) was used to detect the differentially expressed genes
with a cutoff of p < 0.05 and false discovery rate (FDR) < 0.25.
The identified differentially expressed genes were used for
pathway enrichment analysis and functional annotation with
the Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) bioinformatics resources (Huang da et al.,
2009). Heatmaps were generated in R using the gplot package.
GSEA (Subramanian et al., 2005) was performed in MSigDB
to generate the list of the most differentially expressed genes,
including Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway signatures and stem cell signatures. Enriched gene
sets were selected using a cutoff of p < 0.05 and FDR < 0.25
(Isserlin et al., 2014).
Western Blot Analysis
BMSC cell lysates were subjected to western blot analysis.
Isolated proteins were fractionated using NuPAGE 4%–12%
Bis-Tris Gels (Invitrogen) and electrotransferred to polyvinyli-
dene fluoride membranes (Roche). Immunoblots were per-
formed using specific antibodies (Table S2). After incubation
with anti-rabbit immunoglobulin G (IgG) or anti-mouse IgG
(GE Healthcare) antibodies conjugated with horseradish perox-
idase, signals were detected using ECL Chemiluminescence
Substrate (Pierce).
Statistical Analysis
Differences between experimental groups were determined by
Student’s t test or ANOVA followed by Newman-Keuls multiple
comparison tests as appropriate. p Values of less than 0.05 were
considered significant.ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper
is NCBI Gene Expression Omnibus GEO GSE75787 and Genome
Sequence Archive (GSA) in BIG Data Center (BIGD) PRJCA000236.
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